p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis

American Journal of Pathology

Volumn 150, Issue 1, 1997, Pages 177-185

  Tashiro, Hironori ^a   Isacson, Christina ^a   Levine, Ross ^a   Kurman, Robert J ^a   Cho, Kathleen R ^a   Hedrick, Lora ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 17P; CLINICAL ARTICLE; CYSTADENOCARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; PATHOGENESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UTERUS SARCOMA;

AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 17; CYSTADENOCARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION;

EID: 0031012928     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Parker S, Tong T, Bolden S, Wingo PA: Cancer Statistics, 1996, CA Cancer J Clin 1996, 46:5-27
2. Carcangiu ML, Chambers JT: Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma, Gynecol Oncol 1992, 47:298-305
3. Kurman RJ, Zaino RJ, Norris HJ: Endometrial carcinoma. Blaustein's Pathology of the Female Genital Tract, Edited by RJ Kurman, New York, Springer-Verlag, 1994, pp 439-486
4. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ: Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995, 26:1260-1267
5. Sherman ME, Bur ME, Kurman RJ: p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26:1268-1274
6. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC, Marks JR; Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992, 52:1622-1627
7. Kohler MF, Nishii H, Humphrey PA, Sasaki H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A: Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasia. Am J Obstet Gynecol 1993, 169:690-694
8. Ambros RA, Ross JS, Kallakury BVS, Malfetano J, Kim Y, Hwang J, Breese K, Figge J: p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis, Mod Pathol 1995, 8:441-445
9. King SA, Adas AA, LiVoisi VA, Takahashi H, Behbaknt K, McGovern P, Benjamin I, Rubin SC, Boyd J: Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer 1995, 75:2700-2705
10. Remmele W, Schicketanz K-H: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: computer-assisted image analysis (QIC score) vs. subjective grading (IRS), Path Res Pract 1993, 189:862-866
11. Fearon ER, Hamilton SR, Vogelstein B: Clonal analysis of human colorectal tumors, Science 1987, 238:193-197
12. Katabuchi H, van Rees B, Lambers AR, Ronnett BM, Blazes MS, Leach FS, Cho KR, Hedrick L: Mutations in DNA mismatch genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 1995, 55:5556-5560
13. Jones MH, Nakamura Y: Detection of loss of heterozy-gosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes & Cancer 1992, 5:89-90
14. Guzzetta G, Franco B, Trask BJ, Zhang H, Saucedo-Cardenas O, Montes de Oca-Luna R, Greenburg F, Chinault AC, Lupski JR, Patel PI: Somatic cell hybrids, sequence-tagged sites, simple repeat polymorphisms, and yeast artificial chromosomes for physical and genetic mapping of proximal 17p, Genomics 1992, 13:551-559
15. Burks RT, Kessis TD, Cho KR, Hedrick L: Microsatellite instability in endometrial carcinoma. Oncogene 1994, 9:1163-1166
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53
17. Harris CC: 1995 Deichmann lecture-p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Toxicol Lett 1995, 82/83:1-7
18. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development, N Engl J Med 1988, 319:525-532
19. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S-i, Ukita M, Matsuura S: Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 1995, 76:72-78
20. Sundaresan V, Heppell-Parton A, Coleman N, Miozzo M, Sozzi G, Ball R, Gary N, Hasleton P, Fowler W, Rabbitts P: Somatic genetic changes in lung cancer and precancerous lesions. Ann Oncol 1995, 6:S27-S32
21. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992, 52:6079-6082
22. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S-M, Kusters I, Resau JH, Trump BF, Lane DP, Harris CC: p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992, 52:6092-6097
23. Wang LD, Zhou Q, Hong, J-Y, Qiu S-L, Yang CS: p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Cancer 1996, 7:1244-1249
24. Orita M, Suzuki Y, Sekiya T, Hayashi K: A rapid and sensitive detection of point mutations and genetic polymorphism using polymerase chain reaction, Genomics 1989, 5:874-879
25. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JKV, Hamilton S, Vogelstein B: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990, 50:7717-7722
26. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992, 89:7491-7495
27. Kastan MB, Zhan Q, EI-Diery WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell 1992, 71:587-597
28. Lowe SW, Ruley E, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967
29. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature 1993, 362:847-849
30. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giacci AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996, 379:88-91
31. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992, 70:923-935
32. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF: Abnormal centrosome amplification in the absence of p53, Science 1996, 271:1744-1747
33. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X: Uterine papillary serous adenocarcinoma: a 10-case study of p53 and c-erbB-2 expression and DNA content, Cancer 1994, 74:1778-1783